



## **Inauguration of new R&D facility in Mumbai, India by Mr. Jean-Marc Séré-Charlet, Consul General of France- Mumbai**

**September 2022:**

*ATHENA Pharmaceutiques, a technology driven French based pharmaceutical company, specializing in Oral Solid Dosage forms, with existing Manufacturing and R&D operations in India & France is delighted to announce the inauguration of our new R&D facility in Mumbai, India. Mr. Jean-Marc Séré-Charlet, Consul General of France- Mumbai, inaugurated our facility. The foundation to Athena's success over the years is built on its research and development activities in the field of OSD's. This new facility surely opens up broader horizons and enables us as a team to continue our strong legacy in the pharmaceutical field, joyfully declares Mr. Alexandre Williams, Managing director of Athena Pharmaceutiques.*

Here are a few glimpses from the inaugural function:





### **About Athena and Inpharmasci:**

Athena has EU GMP approved facilities in France (Inpharmasci) and India with over 400 staff in Production and R&D. Athena provides product lifecycle management solutions for Oral Solids based on its proprietary technology's platforms viz., Acetyl Cysteine Stick, Bilastine ODT, Bisoprolol + Aspirin, Etifoxine, Fenofibrate, Leucovorine Tablets, Levocetirizine ODT, Ketorolac SL, Mesalasine sachets, Ondansetron ODT, Paracetamol Effervescent, Secnidazole Sachet, Tranexamic Acid Sachets, Racecadotril Sachets, Tramadol +Paracetamol ODT and Zolpidem ODT and SL. These products are already marketed by leading companies across geographies or are under registration.

For further information, please visit: [www.athenapharmaceutiques.com](http://www.athenapharmaceutiques.com)

To contact Athena, please write to us on [contact@ddsathena.com](mailto:contact@ddsathena.com)